{"id":"enoxaparin-followed-by-vka","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Bleeding"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"1-2%","effect":"Injection site reactions (enoxaparin)"},{"rate":"1-3%","effect":"Elevated liver enzymes"},{"rate":"<1%","effect":"Skin necrosis (VKA)"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin works by potentiating antithrombin III to inhibit factors Xa and IIa, preventing thrombus formation. After initial parenteral anticoagulation with enoxaparin, a VKA (such as warfarin) is initiated to provide sustained oral anticoagulation by inhibiting vitamin K-dependent clotting factors (II, VII, IX, X). This sequential approach bridges acute anticoagulation with long-term oral therapy.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting factors, followed by a vitamin K antagonist (VKA) to maintain long-term anticoagulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:55.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism (DVT/PE) treatment and prevention"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT00440193","phase":"PHASE3","title":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Venous Thrombosis","enrollment":3449},{"nctId":"NCT00439777","phase":"PHASE3","title":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Pulmonary Embolism","enrollment":4833}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Enoxaparin followed by VKA","genericName":"Enoxaparin followed by VKA","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting factors, followed by a vitamin K antagonist (VKA) to maintain long-term anticoagulation. Used for Venous thromboembolism (DVT/PE) treatment and prevention, Acute coronary syndrome, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}